Novel melatonin-based treatments for major depression – Authors' reply-Reference-Cited by-同舟云学术

Novel melatonin-based treatments for major depression – Authors' reply

Published:2012-01 Issue:9812 Volume:379 Page:217-219
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hickie Ian B,Rogers Naomi L

Publisher

Elsevier BV

Subject

General Medicine

Reference12 articles.

1. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study;Loo;Int Clin Psychopharmacol,2002

2. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder;Kennedy;Eur Neuropsychopharm,2006

3. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder;Olie;Int J Neuropsychopharmacol,2007

4. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration;Kirsch;PLoS Med,2008

5. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis;Cipriani;Lancet,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conflict of interest in medical journals;Australian Prescriber;2015-02-01

2. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials;British Journal of Psychiatry;2013-09

3. Conflict of interest?;Australian & New Zealand Journal of Psychiatry;2013-03-22

4. Be said to be influenced by personal prejudice (six letters);Australian & New Zealand Journal of Psychiatry;2012-06

5. ‘Interests’ in medicine and the inadequacy of disclosure;Australian & New Zealand Journal of Psychiatry;2012-06